Skip to main content
Aaron Franke, MD, Oncology, Sidney, MT

AaronFrankeMDMS

Oncology • Sidney, MT

Head & Neck Cancer, Thoracic Cancer

Assistant Professor

Join to view full profile

Dr. Franke is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Franke's full profile

Already have an account?

  • Office

    214 14th Ave SW
    PO Box 100278
    Sidney, MT 59270
    Phone+1 406-488-3976

Summary

  • Former Assistant Professor and Associate Research Leader for the Thoracic Cancers Disease Site Group at University of Florida/UF Health Cancer Center.

    Currently practicing general hematology and medical oncology in Sidney, Montana, providing much needed clinical care to the rural MonDak patient population.

Education & Training

  • University of South Florida Morsani
    University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2018 - 2021
  • University of Florida
    University of FloridaResidency, Internal Medicine, 2015 - 2018
  • University of Florida
    University of FloridaInternship, Internal Medicine, 2015 - 2016
  • Saba University School of Medicine
    Saba University School of MedicineClass of 2015
  • Florida State University
    Florida State UniversityBS, Psychology, Physics, 2006 - 2010

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2019 - 2025
  • MT State Medical License
    MT State Medical License 2023 - 2025
  • ME State Medical License
    ME State Medical License 2023 - 2024
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Spotlight Oncologist University of Florida Cancer Awareness and Prevention Network, 2021
  • Exemplary mentor of the year: senior resident teaching award UF College of Medicine, 2018
  • Dean of Clinical Medicine Award 2015
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Lorlatinib rescue therapy for life threatening CNS disease in crizotinib-resistant ROS1-positive NSCLC
    Franke AJ, Nair VS, Shafique M, Mokhtari S., Journal of Thoracic Oncology/2019 IASLC WCLC, Barcelona, Spain, 10/1/2019
  • Predictive clinical and molecular features of long-term survivors receiving immune checkpoint inhibitors for stage 4 NSCLC.
    Franke AJ, Antonia SJ, Haura EB, Chiappori A, Tanvetyanon T, et al., Journal of Thoracic Oncology/IASLC 2019 WCLC, Barcelona, Spain, 10/1/2019
  • Results of a phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response pathway deficient neoplasms.
    George TJ, Lee JH, Hosein PJ....... Franke AJ, et al., JCO/2022 ASCO Annual Meeting, Chicago, IL, 6/1/2022
  • Join now to see all

Lectures

  • Differences in the characteristics of younger and older MSI-H colorectal cancer (CRC) as determined by universal reflex testing. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Authored Content

  • EGFR-Targeted Therapy in Advanced NSCLC Patients With Uncommon EGFR MutationsMay 2023
  • Traveling Through the Lung Cancer Treatment Paradigm: Biomarker Guidance in NSCLCFebruary 2023
  • Traveling Through the Lung Cancer Treatment Paradigm: Moving Cellular Therapies Across SettingsFebruary 2023
  • Current Challenges Facing the Shifting Paradigm of Early-Stage NSCLC ManagementNovember 2022
  • Colorectal Cancer Makeup May Differ by Age Group6/25/2018
  • Join now to see all

Press Mentions

  • FDA Approves Immunotherapy Combination for Metastatic Colorectal Cancer
    FDA Approves Immunotherapy Combination for Metastatic Colorectal CancerJuly 11th, 2018
  • UF study finds younger patients with colorectal cancer less likely to have targetable genetic mutations
    UF study finds younger patients with colorectal cancer less likely to have targetable genetic mutationsNovember 8th, 2022

Committees

  • Appointed Faculty Committee Member, ASCO TAPUR Molecular Tumor Board 2022 - Present
  • Appointed Committee Member, NCI-NCTN NRG Oncology Lung Cancer Committee 2021 - Present
  • Associate Research Leader, UFHCC Thoracic Cancers Disease Site Group 2021 - 2023
  • Voting Member, UFHCC Scientific Review and Monitoring Committee 2021 - 2023
  • Member, UFHCC Cancer Therapeutics Host Response Research Program 2021 - 2023
  • Director, Multidisciplinary Leadership Journal Club 2020 - 2021
  • Board Member, Gator Council Research & ABIM Committee 2016 - 2018

Professional Memberships

Other Languages

  • Spanish

External Links

Dr. Aaron Franke, Dr. Aaron Franke, MD, Dr. A Franke